Ochronosis and Alkaptonuria

Courtesy: Dr Shivshankar Challa, MS, MRCS, Mch

Introduction: Overview of Alkaptonuria

• Alkaptonuria is an extremely rare autosomal recessive metabolic disorder.

• It is caused by deficiency of the enzyme homogentisic acid dioxygenase.

• The condition affects approximately one in two hundred and fifty thousand to one in one million live births.

• Under normal metabolism, homogentisic acid is converted to maleylacetoacetic acid.

• In alkaptonuria, this metabolic pathway is disrupted, leading to:

  • Accumulation of homogentisic acid

  • Deposition of its oxidized product, benzoquinone acetic acid, in collagen-rich tissues

• Excess homogentisic acid is excreted in urine, which:

  • Darkens on standing

  • Darkens on alkalinization

• This urinary discoloration gives the disease its name.

---

Classic Triad of Alkaptonuria

1. Homogentisic aciduria

   • Presence of homogentisic acid in urine

2. Ochronosis

   • Bluish-black pigmentation of connective tissues

3. Ochronotic arthropathy

   • Progressive degenerative joint disease

---

Ochronosis

• Refers to deposition of pigmented metabolic by-products in connective tissues.

• Pigment appears yellow or ochre microscopically.

• Most commonly affects:

  • Hyaline cartilage

• Results in:

  • Cartilage discoloration

  • Structural damage

• Also causes pigmentation of:

  • Eyes

  • Skin

---

Systemic Manifestations of Alkaptonuria

Cardiovascular System

• Coronary artery calcification

• Valvular calcification

• Possible development of aortic stenosis

Respiratory System

• Stiffening of costal cartilage

• Reduced chest expansion

• Exertional breathlessness

Genitourinary System

• Formation of:

  • Renal stones

  • Urethral stones

  • Prostatic stones

Skeletal System

• Osteopenia

• Osteoporosis

• Increased fracture risk

Tendons

• Ochronotic tendinopathy commonly affects:

  • Achilles tendon

  • Patellar tendon

• May lead to:

  • Enthesopathy

  • Spontaneous tendon rupture

---

Ochronotic Arthropathy

General Characteristics

• Most common complication of alkaptonuria.

• Usually asymptomatic until the fourth decade of life.

• Progression correlates with declining renal clearance of homogentisic acid.

Clinical Features

• Progressive joint pain

• Swelling

• Stiffness

• Restricted range of motion

• Functional limitation

• Reduced quality of life

Commonly Affected Joints

• Spine:

  • Cervical region

  • Thoracic region

  • Lumbosacral region

• Peripheral joints:

  • Knee is most frequently affected

---

Historical Perspective of Alkaptonuria

• Fifteen hundred years before the common era

  • Evidence of ochronosis identified in the Egyptian mummy Harwa

• Fifteen eighty-four

  • Scribonius described a child passing black urine

• Eighteen fifty-nine

  • Boedeker coined the term “alcapton” for a reducing urinary substance

• Eighteen sixty-six

  • Rudolf Virchow introduced the term “ochronosis”

• Eighteen ninety-one

  • Wolkow and Baumann identified homogentisic acid

• Nineteen hundred two

  • Albrecht recognized alkaptonuria and ochronosis as manifestations of the same disease

  • Sir Archibald Garrod identified the hereditary nature

• Nineteen hundred eight

  • Garrod described alkaptonuria as the first inborn error of metabolism

• Nineteen hundred nine

  • Neubauer mapped the tyrosine degradation pathway

• Later research confirmed deficiency of homogentisic acid oxidase as the underlying defect.

---

Etiopathology of Ochronotic Arthropathy

Impaired Collagen Cross-Linking

• Benzoquinone acetic acid inhibits lysine hydroxylase.

• Results in reduced collagen cross-linking.

• Produces weak connective tissue susceptible to mechanical stress.

• Leads to cartilage fragmentation.

Synovial Reactions

• Cartilage fragments adhere to synovium, causing:

  • Inflammation

  • Fibrosis

  • Loose body formation

  • Secondary chondromatosis

Altered Cartilage Mechanics

• Pigmented cartilage becomes:

  • Brittle

  • Less elastic

  • Poorly resistant to mechanical loading

Oxidative Stress

• Oxidation of homogentisic acid generates free oxygen radicals.

• Leads to:

  • Inflammation

  • Degeneration

  • Amyloid deposition

Cellular Effects

• Oxidative stress impairs osteoblast function.

• Results in:

  • Autophagy dysfunction

  • Chondrocyte death

Bone Resorption

• Pigment deposition stimulates osteoclastic activity.

• Causes loss of subchondral bone plate.

Impaired Bone Mineralization

• Pigment interferes with osteoid mineralization.

• Results in:

  • Reduced bone mineral density

  • Increased fragility fracture risk

---

Clinical Presentation of Ochronotic Arthropathy

General Pattern

• Predominantly affects:

  • Spine

  • Large weight-bearing joints

• Small joints are usually spared.

• Sacroiliac joints are typically unaffected.

• Absence of:

  • Bamboo spine

  • Annular ossification

  • Syndesmophytes

---

Spinal Involvement

Clinical Features

• Chronic back pain

• Spinal stiffness

• Loss of lumbar lordosis

• Increased thoracic kyphosis

Severity

• More severe disease in individuals positive for human leukocyte antigen B-twenty seven.

Radiological Findings

• Intervertebral disc degeneration

• Multilevel disc calcification

• Vacuum phenomenon

• Possible progression to spinal stenosis with myelopathy

---

Peripheral Joint Involvement

• Occurs years after spinal symptoms.

• Knee is the most commonly involved joint, affecting up to sixty-four percent of patients.

• Upper limb involvement is rare.

Radiological Features

• Severe degenerative changes

• Joint space narrowing

• Subchondral sclerosis

• Minimal or absent osteophyte formation

Synovial Fluid Findings

• Presence of floating black particles

• Known as the “ground pepper sign”

---

Rare Associated Conditions

• Rheumatoid arthritis

• Ankylosing spondylitis

• Chondrocalcinosis

---

Treatment of Alkaptonuria and Ochronotic Arthropathy

General Principles

• No definitive cure exists.

• Treatment focuses on:

  • Reducing homogentisic acid levels

  • Symptom control

  • Prevention of complications

---

Conservative Management

Dietary Protein Restriction

• Reduces homogentisic acid excretion.

• May improve bone metabolism.

• Difficult to maintain long term.

Ascorbic Acid Supplementation

• May reduce oxidation of homogentisic acid.

• Supports collagen health.

---

Nitisinone Therapy

• First disease-modifying therapy approved for alkaptonuria.

• Approved in Europe in two thousand twenty.

• Previously approved for hereditary tyrosinemia type one.

Mechanism of Action

• Inhibits four-hydroxyphenylpyruvate dioxygenase.

• Reduces production of homogentisic acid.

Clinical Trial Evidence

• Significant reduction in urinary homogentisic acid levels.

• Improvement in clinical symptoms and biochemical markers.

• Limited effect on preventing secondary amyloidosis.

---

Symptomatic and Supportive Care

• Physiotherapy to preserve joint mobility.

• Pain control using non-steroidal anti-inflammatory drugs.

• No effect on disease progression.

---

Surgical Management

• Indicated in end-stage ochronotic arthropathy.

• Total joint replacement is the most effective option.

• Most commonly performed for:

  • Hip joints

  • Knee joints

---

Case Summary: Middle-Aged Female with Polyarticular Ochronotic Arthropathy

Clinical Timeline

• Two thousand sixteen (Age fifty-three)

  • Bilateral anatomic total shoulder replacement

• Two thousand twenty (Age fifty-seven)

  • Severe right hip pain and weight-bearing difficulty

  • Magnetic resonance imaging showed:

    • Osteonecrosis of femoral head

    • Advanced hip arthritis

  • Cementless right total hip replacement performed

Intraoperative Findings

• Black discoloration of:

  • Joint capsule

  • Femoral head

  • Synovium

• Complete cartilage separation

• Diagnosis confirmed as ochronotic arthropathy

---

Postoperative Complication

• Six weeks later:

  • Severe left hip pain

  • Rapid cartilage destruction

• Treated with cementless left total hip replacement.

• Similar intraoperative findings noted.

---

Postoperative Recovery

• Mobilized pain-free with crutches on first postoperative day.

• Intensive physiotherapy and gait training.

• Walking aids discontinued within three weeks.

---

Outcome at Two-Year Follow-Up

• No hip pain

• Full range of motion

• Independent in daily activities

• No implant loosening or subsidence

• Persistent back pain due to advanced spinal degeneration

---

Summary of Arthroplasty Outcomes in Ochronotic Arthropathy

• Multiple published reports demonstrate:

  • Excellent short- and long-term outcomes

  • Successful hip, knee, and shoulder replacements

• Cementless arthroplasty shows:

  • Good implant stability

  • No increased complication rate

• Surgical considerations:

  • Total synovectomy is recommended

  • Preservation of joint capsule improves stability

---

Final Conclusion

• Alkaptonuric ochronosis is an ultra-rare and disabling metabolic disorder.

• It leads to progressive polyarticular joint destruction.

• Affects relatively young individuals.

• Cementless, bone-preserving total joint replacement:

  • Provides reliable pain relief

  • Restores function

  • Offers excellent long-term outcomes

• Total joint replacement remains the most effective treatment for end-stage ochronotic arthropathy.